PBS Biotech
Bridging Science and Scale in Cell Therapy Manufacturing
Martin Simonetti, CEO
Cell Therapy Product Development
Cell therapy product development helps life sciences companies advance cell-based treatments from research concepts toward clinical use. With a focus on process design, quality control, scalability and regulatory readiness, it supports stronger therapeutic development and more reliable clinical translation.
Solutions
In the cell therapy industry, success is measured not just by scientific breakthroughs but by the ability to deliver therapies safely, efficiently, and predictably to patients. PBS Biotech, headquartered in Camarillo, CA, has made it its mission to ensure that this transition from research to medicine is seamless.
State of Industry
Personalized Healing: The Evolution and Future of Cell Therapy
Cell therapy products are redefining the boundaries of modern medicine, shifting treatment paradigms from symptom management to targeted, regenerative intervention. Unlike conventional therapies that rely on standardized formulations, cell-based treatments operate at a biological level, using living cells to repair, replace, or enhance human function. For CEOs and business leaders, this sector represents a convergence of biotechnology innovation, manufacturing complexity, and strategic commercialization challenges.
Deep Dive
Scaling Cell Therapy from Research to Reliable Manufacturing
Cell therapy development has moved beyond proof-of-concept science into the demands of repeatable manufacturing and clinical delivery. For executives responsible for advancing these programs, the challenge no longer sits solely in demonstrating biological efficacy but in ensuring that therapies can be produced consistently, economically and at scale without introducing new risks at each stage of growth. Many programs falter not because the underlying biology fails, but because the transition from laboratory processes to production environments introduces variability, cost escalation and regulatory friction that were not addressed early enough.
Leadership Perspective
University of Pennsylvania Health System
From Data to Delivery: Scaling Access to Cell Therapy
Robert Richards, Corporate Director of The Center for Cell Therapy and Transplant, Penn Medicine
A bit of context, I am an engineer by education. I have been in healthcare for 25 years, first working for medical oncologists in a private practice. I was with that group for 16 years. The practice was an innovative and forward-thinking group; I was hired to help them implement an EMR before EMRs were mainstream. Over time, I found myself less interested in the systems and software and more interested in learning and understanding oncology. I would tell the physicians that, while the EMR would help them practice medicine better, the true value is that the data collected would help them run their business better and inform them of clinical “behaviors.” That held true in the latter years, when the practice was in financial straits, and it was the data that identified some of the issues. I ascended to managing the overall practice and was asked to address the financial issues. While I was able to stabilize the practice, the marketplace was changing. Bigger institutions were coming into the practice catchment area and shifting the market unfavorably to the group. In 2016, I/we sold the practice to the University of Pennsylvania Health System. I had no intentions of staying with Penn; I was going to go do something on my own. Before that happened, I met Dr. David Porter, the Director of BMT, who had a vision of developing a freestanding Center for Cell Therapy that supports these treatments beyond cancer. That’s where we are today.
Cell Therapy Product Development Info
Q1
What Do Top Cell Therapy Product Development Companies Do?
Top Cell Therapy Product Development Companies help therapy developers move living-cell products from research concepts toward reproducible, scalable and regulated production. Their work may support cell culture, process design, expansion systems, closed workflows, quality controls and manufacturing readiness. Because cell therapies are sensitive to handling, environment and consistency, the category focuses on practical development paths that protect product integrity while preparing programs for clinical or commercial requirements.
Q2
What Services and Solutions Are Included in Cell Therapy Product Development?
Cell therapy product development can include process optimization, bioreactor selection, media strategy, scale-up planning, documentation support, analytical coordination and equipment integration. Top Cell Therapy Product Development Companies may also help teams compare manual, semi-automated and closed-system approaches before larger manufacturing investments are made. The aim is to reduce uncertainty early, so scientific teams can make better decisions about yield, consistency, contamination control and future facility needs.
Q3
Why Is Demand Rising for Cell Therapy Development Partners?
Demand is rising as more cell-based programs move from discovery into translational, clinical and commercial planning. Top Cell Therapy Product Development Companies are important because developers need reliable ways to increase output without compromising cell quality or process control. Growth is also shaped by pressure to shorten development timelines, manage complex regulatory expectations and make advanced therapies more practical for broader patient populations.
Q4
How Are Leading Cell Therapy Product Development Companies Evaluated?
Leading cell therapy product development companies are often evaluated by their process expertise, scalability, quality mindset, regulatory awareness and ability to support different therapeutic platforms. Top Cell Therapy Product Development Companies should show that their systems or services can connect early development work with later manufacturing expectations. Decision-makers may also consider documentation discipline, technical support, customization capacity, contamination-risk reduction and compatibility with GMP-oriented workflows.
Q5
How Do Cell Therapy Development Solutions Create Value?
Cell therapy development solutions create value by improving process reliability before costly clinical or commercial commitments are made. Top Cell Therapy Product Development Companies can help reduce failed scale-up attempts, avoid avoidable downtime and support more consistent production outcomes. For therapy developers, that value may appear in clearer process parameters, better resource planning, stronger quality controls and a more credible path from laboratory work to patient-focused manufacturing.
Q6
What Role Do Innovation and Technical Expertise Play in This Category?
Innovation and technical expertise are central because cell therapy development depends on controlling living biological materials under changing scale, timing and quality demands. Top Cell Therapy Product Development Companies may advance the category through automation, single-use systems, parallel testing, real-time monitoring, low-shear handling and data-supported process control. Strong expertise helps translate these tools into workable development strategies rather than isolated technologies.
